<?xml version='1.0' encoding='utf-8'?>
<document id="26956546"><sentence text="Single concentration loss of activity assay provides an improved assessment of drug-drug interaction risk compared to IC50-shift." /><sentence text="1" /><sentence text=" The utility of two abbreviated, higher-throughput assays [IC50-shift and the loss of activity (LOA) assay] to evaluate time-dependent inhibition (TDI) of 24 structurally related compounds was compared" /><sentence text=" 2" /><sentence text=" Good correlation (R(2)  = 0" /><sentence text="90) between % inhibition and kinact/KI suggested that the LOA assay has utility as an indicator of TDI potential" /><sentence text=" Weaker correlation was observed for the shifted IC50 (IC50(T = 30)) (R(2) = 0" /><sentence text="61) and the fold-shift in IC50 (R(2) = 0" /><sentence text="17)" /><sentence text=" 3" /><sentence text=" Primary mechanism for poor correlation was depletion of active enzyme at concentrations &gt; 1 μM leading to greater than predicted inhibition in the IC50-shift assay" /><sentence text=" 4" /><sentence text=" Previously reported strong correlations between IC50(T = 30) and kinact/KI were found to be dependent on potent TDI compounds with kinact/KI &gt; 30; correlation was reduced for moderate inhibitors (kinact/KI &lt; 30)" /><sentence text=" LOA assay maintained good correlation even when strong TDI compounds were excluded" /><sentence text=" 5" /><sentence text=" LOA assay (% Inhibition at 30 min, 10 μM) was a good predictor of in vivo DDI (AUCr), providing a graded response with low potential for false negatives or positives" /><sentence text=" IC50-shift assay had bias for over-predicting in vivo DDI and was more likely to identify false positives" /><sentence text=" " /></document>